In mice, administration of a TLR9 antagonist protected from NASH, but it was also suggested that it was host mitochondrial DNA rather than bacterial DNA that activated this receptor in disease (Garcia‐Martinez et al, 2016). This evidence concerns the gene TLR9 and metabolic dysfunction-associated steatohepatitis.